Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MRUSNASDAQ:OPTNASDAQ:SOPHNASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRUSMerus$53.84+1.0%$49.89$33.19▼$62.98$3.73B1739,450 shs222,443 shsOPTOpthea$3.41+7.2%$3.41$1.90▼$6.30$524.84M1.1726,647 shs3,000 shsSOPHSOPHiA GENETICS$2.99-1.6%$3.01$2.58▼$4.92$199.39M158,708 shs63,099 shsSRRKScholar Rock$35.35-0.6%$32.40$6.76▼$46.98$3.42B0.331.30 million shs481,993 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRUSMerus0.00%+1.60%-6.50%+41.28%+1.68%OPTOpthea0.00%0.00%0.00%0.00%+80.42%SOPHSOPHiA GENETICS0.00%-3.24%-0.33%+8.33%-35.84%SRRKScholar Rock0.00%-1.28%+14.70%+31.41%+354.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMRUSMerus1.8603 of 5 stars3.61.00.00.01.42.50.0OPTOpthea0.3765 of 5 stars1.10.00.00.02.20.80.6SOPHSOPHiA GENETICS2.3904 of 5 stars3.35.00.00.01.10.00.6SRRKScholar Rock3.3423 of 5 stars2.60.00.04.41.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRUSMerus 3.14Buy$84.6457.20% UpsideOPTOpthea 2.17Hold$1.33-60.90% DownsideSOPHSOPHiA GENETICS 2.67Moderate Buy$7.00134.11% UpsideSRRKScholar Rock 3.14Buy$42.6720.70% UpsideCurrent Analyst Ratings BreakdownLatest OPT, SRRK, SOPH, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.006/3/2025SRRKScholar RockLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/23/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$96.00 ➝ $110.005/19/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.005/14/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.005/8/2025MRUSMerusWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.004/28/2025MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/9/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$83.00 ➝ $83.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRUSMerus$36.13M103.13N/AN/A$9.46 per share5.69OPTOpthea$120K4,373.61N/AN/A($0.56) per share-6.09SOPHSOPHiA GENETICS$65.17M3.06N/AN/A$1.48 per share2.02SRRKScholar Rock$33.19M101.13N/AN/A$3.94 per share8.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRUSMerus-$215.33M-$4.080.00N/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)OPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/A8/28/2025 (Estimated)SOPHSOPHiA GENETICS-$62.49M-$1.000.00N/AN/A-98.51%-63.47%-40.06%8/5/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.530.00N/AN/AN/A-118.22%-82.01%8/6/2025 (Estimated)Latest OPT, SRRK, SOPH, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/14/2025Q1 2025SRRKScholar Rock-$0.63-$0.67-$0.04-$0.67N/AN/A5/6/2025Q1 2025SOPHSOPHiA GENETICS-$0.21-$0.26-$0.05-$0.26$16.76 million$17.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMRUSMerusN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRUSMerusN/A5.865.86OPTOptheaN/A1.57N/ASOPHSOPHiA GENETICS0.163.112.94SRRKScholar Rock0.1610.2510.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRUSMerus96.14%OPTOpthea55.95%SOPHSOPHiA GENETICS31.59%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipMRUSMerus4.57%OPTOpthea3.20%SOPHSOPHiA GENETICS4.88%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMRUSMerus3769.21 million66.05 millionOptionableOPTOpthea8153.91 million148.99 millionNot OptionableSOPHSOPHiA GENETICS52066.69 million63.43 millionNot OptionableSRRKScholar Rock14094.95 million82.32 millionOptionableOPT, SRRK, SOPH, and MRUS HeadlinesRecent News About These CompaniesScholar Rock Holding Corporation (SRRK) - Yahoo FinanceJuly 4 at 3:47 AM | finance.yahoo.comJeffrey S. Flier Sells 11,136 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) StockJune 26, 2025 | insidertrades.comJeffrey S. Flier Sells 11,136 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) StockJune 25, 2025 | marketbeat.comInsider Selling: Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Sells 20,316 Shares of StockJune 25, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Shares Up 5.2% - Time to Buy?June 25, 2025 | marketbeat.comScholar Rock Holding Corp. (SRRK) Stock Price Today - WSJJune 24, 2025 | wsj.comScholar Rock Holding Corp News (SRRK) - Investing.comJune 24, 2025 | investing.comScholar Rock CEO on its drug that could preserve muscle in weight-loss drug usersJune 24, 2025 | youtube.comYScholar Rock: EMBRAZE Results Drive The Stock HigherJune 23, 2025 | seekingalpha.comScholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from AnalystsJune 21, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Shares Down 5.7% - Should You Sell?June 20, 2025 | marketbeat.comScholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug TrialJune 19, 2025 | insidermonkey.comScholar Rock data show promise for muscle-preserving combo with ZepboundJune 19, 2025 | thepharmaletter.comTScholar Rock (NASDAQ:SRRK) Receives Outperform Rating from WedbushJune 18, 2025 | marketbeat.comScholar Rock says its drug preserved lean mass in patients taking ZepoundJune 18, 2025 | statnews.comSScholar Rock Jumps on Weight Loss Data for Zepbound/Repurposed Antibody ComboJune 18, 2025 | biospace.comBScholar Rock's SMA drug helps weight loss patients on Zepbound retain muscle in phase 2 trialJune 18, 2025 | fiercebiotech.comFScholar Rock stock soars after drug shows promise in preserving lean mass during weight lossJune 18, 2025 | au.investing.comScholar Rock lead asset causes higher quality weight loss with Lilly’s obesity drugJune 18, 2025 | msn.comScholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial ResultsJune 18, 2025 | msn.comScholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight LossJune 18, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesThe Other AI Chipmaker: Why Marvell's Dip Is a BuyBy Jeffrey Neal Johnson | June 12, 2025View The Other AI Chipmaker: Why Marvell's Dip Is a BuyReddit Stock Ignites: Surge in Call Options Signals Big BetBy Gabriel Osorio-Mazilli | June 24, 2025View Reddit Stock Ignites: Surge in Call Options Signals Big BetSnowflake Hits 52-Week High—Options Traders Bet on Further RallyBy Gabriel Osorio-Mazilli | June 29, 2025View Snowflake Hits 52-Week High—Options Traders Bet on Further RallyAlibaba Call Options Surge, New Hopes of a Trade Deal?By Gabriel Osorio-Mazilli | June 19, 2025View Alibaba Call Options Surge, New Hopes of a Trade Deal?Zscaler Upgraded: Wall Street Forecasts 26% More UpsideBy Gabriel Osorio-Mazilli | June 17, 2025View Zscaler Upgraded: Wall Street Forecasts 26% More UpsideOPT, SRRK, SOPH, and MRUS Company DescriptionsMerus NASDAQ:MRUS$53.84 +0.51 (+0.96%) Closing price 07/3/2025 01:04 PM EasternExtended Trading$53.38 -0.46 (-0.85%) As of 07/3/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Opthea NASDAQ:OPT$3.41 +0.23 (+7.23%) As of 07/3/2025 02:20 PM EasternOpthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.SOPHiA GENETICS NASDAQ:SOPH$3.00 -0.04 (-1.35%) As of 07/3/2025 01:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.Scholar Rock NASDAQ:SRRK$35.35 -0.20 (-0.56%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$35.35 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
